Celldex Therapeutics, Inc. (CLDX)

Celldex Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan 30, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	1,635	1,677	2,169	2,099	1,803	693
Market Cap Growth	8.93%	-22.71%	3.32%	16.42%	160.10%	1759.97%
Enterprise Value	1,054	924	1,936	1,779	1,383	497
Last Close Price	24.60	25.27	39.66	44.57	38.64	17.52
PS Ratio	628.96	238.82	315.12	890.64	387.68	93.45
PB Ratio	2.73	2.24	5.05	6.44	4.30	3.31
P/TBV Ratio	2.86	2.33	5.40	7.02	4.60	3.88
EV/Sales Ratio	405.56	131.57	281.34	754.94	297.37	67.06
Debt / Equity Ratio	0.00	0.01	0.01	0.01	0.01	0.02
Asset Turnover	0.00	0.01	0.02	0.01	0.01	0.04
Quick Ratio	12.55	18.38	13.69	16.41	24.71	13.81
Current Ratio	13.01	18.92	13.87	17.07	24.86	13.93
Return on Equity (ROE)	-32.44%	-26.84%	-37.45%	-30.13%	-22.43%	-39.41%
Return on Assets (ROA)	-21.77%	-19.38%	-21.70%	-16.79%	-12.70%	-17.27%
Return on Capital Employed (ROCE)	-42.60%	-25.90%	-32.70%	-32.10%	-16.20%	-22.40%
Earnings Yield	-13.74%	-9.42%	-6.52%	-5.35%	-3.91%	-8.62%
FCF Yield	-11.11%	-9.53%	-5.03%	-5.03%	-3.45%	-6.05%
Buyback Yield / Dilution	-9.16%	-32.91%	-3.33%	-9.37%	-44.64%	-104.31%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q